Resolutions at the Annual General Meeting in Medivir on 9 May 2019

News provided by

May 09, 2019, 10:40 ET

HUDDINGE, Sweden, May 9, 2019 /PRNewswire/ -- Approval of profit and loss accounts and balance sheets, and discharge from liability of the board members and the managing director
The annual general meeting in Medivir Aktiebolag (publ) on 9 May 2019 resolved to approve the profit and loss account and balance sheet as well as the consolidated profit and loss account and consolidated balance sheet for the financial year 2018. The persons who had been board members and CEO were discharged from liability with respect to their respective management of the company for the financial year 2018.

Appropriation of the company's profit or loss
The annual general meeting resolved, in accordance with the board's proposal, that the company's results shall be carried forward.

Remuneration to the board of directors and auditor
The annual general meeting also resolved on remuneration to the board of directors in accordance with the nomination committee's proposal. The remuneration to the board shall be paid with a total yearly amount of not more than SEK 1,610,000, allocated as follows. The chairman shall receive SEK 650,000 and other members who are not employed by the company shall receive SEK 240,000 each. Remuneration for work performed in relation to committees shall not be paid. The annual general meeting also resolved that remuneration to the auditor shall be paid in accordance with approved invoices within the auditor's quotation.

Election of the board of directors and auditor
The annual general meeting resolved, in accordance with the nomination committee's proposal, that the number of board members shall be six with no deputy board members. Uli Hacksell, Lennart Hansson, Bengt Julander, Helena Levander and Bengt Westermark were re-elected and An van Es Johansson was newly elected as members of the board. Anna Malm Bernsten and Anders Hallberg had declined re-election. Helena Levander was elected new chairman of the board. Öhrlings PricewaterhouseCoopers AB was re-elected as auditor.

Nomination committee
The annual general meeting resolved to appoint a nomination committee for the annual general meeting 2020 substantially in accordance with the same procedure as the preceding year. In brief, this entails that the chairman of the board shall contact the three largest shareholders in respect of voting power by the end of the third quarter. These three shareholders shall be offered to appoint one member each for the nomination committee. In addition, the chairman of the board shall be included as a member of the nomination committee.

Remuneration guidelines for senior executives
The annual general meeting approved the proposal of the board of directors on remuneration guidelines for senior executives. Under the guidelines, the company shall offer a total remuneration on market norms and enable skilled senior executives to be hired and retained. The remuneration to senior executives may consist of basic salary, variable salary, incentive programmes resolved by the general meeting, pension and other benefits.

Authorization on new share issues
The annual general meeting finally approved the proposal of the board of directors to authorize the board to resolve to issue new shares of series B. The total number of shares that may be issued under the authorization must total not more than 20 percent of the total number of shares outstanding in the company following exercise of the authorization. The purpose of the authorization is to provide the board with flexibility in its work to secure that the company, in a suitable way, can be provided with capital for the financing of the operations. Issuances of new shares under the authorization shall be made on market terms and conditions.

For further information, please contact:
Uli Hacksell, CEO, phone: 46 (0)73 125 0615.

About Medivir
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The company is investing in indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Collaborations and partnerships are important parts of Medivir's business model and the drug development as well as the commercialization is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.